SCHEMBL379876

SCHEMBL379876

Cc1ccc(-c2csc3c(-c4ccncc4)cnc(NCc4ccccc4)c23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.47
KDR P35968 3/20 0.46
CCNC P24863 1/20 0.44
CDK8 P49336 1/20 0.44
ESR1 P03372 1/20 0.44
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
BRAF P15056 1/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PIP4K2C Q8TBX8 1/20 0.42
AURKB Q96GD4 1/20 0.42
CYP3A4 P08684 3/20 0.42
MAPT P10636 2/20 0.42
MAPK1 P28482 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379874 0.96 CCNC (0.47) BTKKDRCCNCCDK8ESR1
SCHEMBL379662 0.94 CCNC (0.49) BTKKDRCCNCCDK8ESR1
SCHEMBL379554 0.92 BRAF (0.52) KDRCCNCCDK8ESR1PDE4A
SCHEMBL379543 0.90 THRB (0.44) KDRCCNCCDK8ESR1TP53
SCHEMBL379469 0.90 ESR1 (0.49) BTKKDRCCNCCDK8ESR1
SCHEMBL379842 0.89 CYP1A2 (0.54) BTKKDRCCNCCDK8ESR1
SCHEMBL379872 0.86 CCNC (0.42) KDRCCNCCDK8ESR1BRAF
SCHEMBL379860 0.86 CCNC (0.42) BTKKDRCCNCCDK8ESR1
SCHEMBL380180 0.86 ESR1 (0.50) KDRCCNCCDK8ESR1BRAF
SCHEMBL379947 0.86 KDR (0.45) BTKKDRCCNCCDK8ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US claimed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 BTK 4027/4885KDR 2522/4885CCNC 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.